Clinical Trial Update: A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients [Phase 1]

View source ↗

Summary

Phase I trial evaluating Niraparib given concurrently with postoperative radiotherapy in patients with triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Triple Negative Breast Cancer, Residual Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING